Core technologies
To help the skin restore its healthy state, it is important not only to add beneficial ingredients, but also to create an environment in which they can work effectively. Chitogen™ was developed on this principle — it stabilizes the skin and tissue microenvironment, creating an optimal foundation for other active ingredients to work more effectively.
CORE TECHNOLOGY 01
Conventional chitosan dissolves only under acidic conditions, which has limited its use in injectable applications. MEDIFAB introduced carboxymethyl groups into chitosan to enable stable dissolution in neutral water and physiological environments.
CORE TECHNOLOGY 02
Maintains a neutral, liquid state before application. Once absorbed, it reacts with the skin's ionic environment and transforms into a dense gel matrix, helping active ingredients remain localized within the skin for longer.
| Material | Key characteristics | Limitations | Chitogen™ differentiation |
|---|---|---|---|
| Chitosan | Excellent biocompatibility and antimicrobial properties [6–8] | Soluble only under acidic conditions, limiting injectable use [6–8] | Carboxymethyl chitosan enables solubility in neutral environments |
| PLLA | Biodegradable polymer that induces collagen production [1–3] | Particle-based formulation requiring reconstitution; tissue reactions reported [1–3] | A liquid formulation enables more uniform injection |
| PDLLA | More uniform degradation compared with PLLA [1–3] | Particle-based formulation with potential for early tissue reaction [1–3] | A uniform, non-particulate liquid supports even distribution within tissue |
| PDRN | Used for tissue recovery and skin improvement [4,5] | Relatively rapid in vivo degradation may limit persistence [4,5] | LTG technology forms a gel in vivo, providing a stable delivery environment |
| Exosome | Bioactive vesicles supporting intercellular signaling [5] | Manufacturing standardization, consistency and storage stability remain challenges [5] | Nano-reservoir structure helps prevent premature degradation across a range of bioactives |
Reference
[1] Journal of Cutaneous and Aesthetic Surgery (JCAS), 2026. [2] Cureus, 2026. [3] StatPearls, 2024. [4] PubMed PMID: 39339047, 2024. [5] PMC11644387, 2024. [6] Biomaterials, 2002. [7] Environmental Chemistry Letters, 2019. [8] Macromolecular Bioscience, 2022.
Patents
2020
Thermosensitive chitosan hydrogel composition and bioink composition comprising the same (KR Registered)
2022
Composition for manufacturing thermosensitive tissue-repair biomaterial and its use (KR Registered)
2022 · PCT 2022
Composition for manufacturing multi-crosslinked thermosensitive hydrogel and its use (KR Registered)
2024 · PCT 2024
In-vivo ion-sensitive tissue-repair biomaterial composition (KR Registered · JP/US/CN/EU 2026)
2026
Composition for degradation or correction of tissue-repair biomaterial (KR Registered)
Publications
2022
Novel Chitosan Dermal Filler with Enhanced Moldability and Elasticity. Macromolecular Bioscience
GOV Projects
2020. 04 - 2021. 03
4th-generation filler technology based on thermosensitive hydrogel (Ministry of Science and ICT)
2020. 04 - 2021. 12
Commercialization of filler products using thermosensitive hydrogel manufacturing technology (KHIDI)
2020. 07 - 2022. 07
Development of functional hydrogel biomaterials for tissue repair (related program)
Even in a favorable environment, cells cannot initiate an appropriate healing response without the biological signals required for repair. Regentrix™ delivers ECM-derived signals that damaged tissue can recognize, supporting the tissue's natural recovery process. Derived from porcine dermis — structurally the closest match to human skin — cellular components that could trigger an immune response are removed while over 80% of key ECM components are preserved.
CORE TECHNOLOGY 01
Unlike conventional decellularization methods that use surfactants such as SDS and Triton X, the process uses none — minimizing the risk of surfactant residues and producing dECM suitable for human application.
CORE TECHNOLOGY 02
Telopeptides, which can induce immune responses, are removed through a proprietary process, creating a dECM platform that can be formulated as either a powder or a water-soluble form.
| Comparison item | Regentrix™ | Conventional human-derived dECM |
|---|---|---|
| Core material | Porcine dermis-derived dECM | Human tissue-derived dECM |
| Manufacturing process | Supercritical CO₂-based decellularization | Varies by manufacturer and process |
| Quality consistency | Standardized raw material and process | May vary with donor characteristics |
| ECM retention | Over 80% retained vs. original tissue | Retention rate may vary by process |
| Supply stability | Secured through HACCP-certified sourcing | May fluctuate with donation availability |
| Ethical considerations | Commercially farmed raw material | Considerations tied to the use of human tissue |
Reference
Kim et al., Advanced Healthcare Materials (2026), e04383.
Patents
2023 · PCT 2024
Water-soluble decellularized matrix based on a supercritical CO₂ process (KR Filed · JP/US/CN/EU 2025)
2025 · PCT 2024
Method for manufacturing a decellularized matrix with enhanced biocompatibility (KR Registered · JP/US/CN/EU 2026)
Publications
2026
Amine-functionalized chitosan/dECM composite promotes cutaneous regeneration and hair follicle activation. Adv. Healthcare Mater., e04383
2025
Supercritical fluid-processed hybrid dECM with chitosan hydrogel for improving photoaged dermis. Adv. Healthcare Mater.
GOV Projects
2020. 04 - 2024. 12
Regenerative medicine product commercialization via tissue-derived ECM bioink (KEIT)
2022. 05 - 2024. 04
Dual-crosslinked injectable filler containing decellularized adipose tissue (TIPA)
Chitogenix™ combines Chitogen™, which creates an optimal regenerative environment, with Regentrix™, which delivers ECM-derived regenerative signals. Instead of simply adding active ingredients or applying external stimulation, Chitogenix™ designs the conditions and the signals together, helping cells support their own recovery. In WST assays using human dermal fibroblasts, it recorded the highest cell viability across every H₂O₂ concentration tested.
CELL VIABILITY
vs. 25.4% non-treated, 36.5% HA and 58.5% PDRN — WST assay using human dermal fibroblasts.
OXIDATIVE STRESS
The lowest residual level among all tested formulations, confirmed by DCFH-DA staining.
Chitogen™ creates the environment in which regeneration can happen. Regentrix™ delivers the signals that tell cells what to do. Chitogenix™ designs both together, helping cells support their own recovery processes.
Patents
2023 · PCT 2024
Composition comprising a chitosan derivative and decellularized ECM hydrolysate (KR Filed · JP/US/CN/EU 2026)
Publications
2026
Amine-functionalized chitosan/dECM composite promotes cutaneous regeneration and hair follicle activation. Adv. Healthcare Mater., e04383
GOV Projects
2024. 06 - 2028. 12
High-strength organic-inorganic hybrid bone regeneration material with osteoimmune regulation (KEIT)
2025. 07 - 2027. 12
Hybrid osteoarthritis treatment with steroid-alternative anti-inflammatory and cartilage-preserving properties (KEIT)